Speakers

Ali Osmay Gure

Place of Birth : Turkey
Born : 1964
Position : Chair of the Molecular Biology and Genetics Department at Bilkent University, Turkey
Field of study : Cancer serology, cancer epigenetics, Cancer biomarkers of prognosis and chemosensitivity
H. Index : 30

Dr. Ali Gure is the chair of the Molecular Biology and Genetics Department of Bilkent University, Ankara, Turkey. He is a medical doctor (University of Ankara) and a molecular immunologist (Cornell University Graduate School of Medical Sciences). He was a post-doctoral fellow at the Memorial Sloan Kettering Research Center, and the Department of Pathology of the Weill Cornell Medical College in NYC from 1995 to 2000 when he was involved in the discovery of antigenic tumor proteins. He was an Assistant Member at the NY branch of the Ludwig Institute for Cancer Research from 2000 to 2006, when he continued working on tumor antigens, with an emphasis on the regulation of Cancer-Testis gene expression in cancer, and the clinical relevance of this. Since 2006, after joining the Bilkent MBG faculty, he started in silico analysis of tumor data aiming to find correlations of these with the clinical outcome with a focus on triple-negative breast cancer, colon and lung cancer, in particular. He is a partner of Poyraz Biotech Ltd., a biotech company founded by his students, which focuses on the large scale validation of clinically relevant tumor biomarkers. He is a co-inventor on more than 25 international patents related to tumor antigens/biomarkers.  His work has been supported by the European Commission, the Ludwig Institute for Cancer Research, the Cancer Research Institute (USA) and the Turkish Scientific and Medical Council (TUBITAK).

• Dr. Ali Gure was involved in the discovery of antigenic tumor proteins.

• His work has been supported by the European Commission, the Ludwig Institute for Cancer Research, the Cancer Research Institute (USA) and the Turkish Scientific and Medical Council (TUBITAK).